StageZero Life Sciences (SZLSF) Stock Price, News & Analysis

Company Overview

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

Key Stats

• Today's Range: $0.0030 to $0.0030
• 50-Day Range: $0.00 to $0.05
• 52-Week Range: $0.00 to $1.00
• Volume: 3,000 shs
• Average Volume: 1,887 shs
• Market Capitalization: $370,599.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SZLSF Stock Analysis - Frequently Asked Questions

How have SZLSF shares performed this year?

StageZero Life Sciences' stock was trading at $0.0016 at the start of the year. Since then, SZLSF shares have increased by 87.5% and is now trading at $0.0030.
View the best growth stocks for 2025 here.

How do I buy shares of StageZero Life Sciences?

Shares of SZLSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SZLSF
• CIK: 1454263
• Web: www.stagezerolifesciences.com
• Phone: (855) 420-7140
• Fax: 905-209-2031
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: $3.80 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 123,533,000
• Free Float: 120,395,000
• Market Cap: $370,599.00
• Optionable: Not Optionable
• Beta: -2.12